🇺🇸 FDA
Pipeline program

A Phase 1b Study of AMG 757 in Subjects with Neuroendocrine Prostate Cancer

20200040

Phase 1 other active

Quick answer

A Phase 1b Study of AMG 757 in Subjects with Neuroendocrine Prostate Cancer for Adult subjects with de novo or treatment-emergent neuroendocrine prostate cancer is a Phase 1 program (other) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).

Program details

Company
Amgen Technology (Ireland) UC
Indication
Adult subjects with de novo or treatment-emergent neuroendocrine prostate cancer
Phase
Phase 1
Modality
other
Status
active

Clinical trials